Developing new gene therapy methods to potentially cure HIV
Evolving Novel AAV Vectors for Gene Therapy to Cure HIV
['FUNDING_R01'] · OREGON HEALTH & SCIENCE UNIVERSITY · NIH-11092775
This study is testing new ways to use special viruses to help deliver treatments for HIV, aiming to improve how well these therapies work and possibly lead to a cure for patients.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | OREGON HEALTH & SCIENCE UNIVERSITY (nih funded) |
| Locations | 1 site (PORTLAND, UNITED STATES) |
| Trial ID | NIH-11092775 on ClinicalTrials.gov |
What this research studies
This research focuses on creating innovative adeno-associated virus (AAV) vectors that can deliver gene therapies to immune cells, specifically targeting HIV. By utilizing a novel directed evolution technique, the researchers aim to enhance the delivery of Leronlimab, an antibody that mimics a CCR5-deficient immune system, which has shown promise in curing HIV in specific cases. The study also explores the potential of these vectors to support other advanced therapies, such as CRISPR-Cas9 and chimeric antigen receptors, to combat HIV more effectively. Patients may benefit from a future where HIV can be treated more effectively or potentially cured through these new gene therapy approaches.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals living with HIV who are seeking innovative treatment options beyond traditional antiretroviral therapy.
Not a fit: Patients who are not living with HIV or those who have already achieved viral suppression through existing therapies may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to a functional cure for HIV, significantly improving the lives of those living with the virus.
How similar studies have performed: While the approach of using AAV vectors for gene therapy is being explored, the specific application to HIV treatment is relatively novel and has not been widely tested.
Where this research is happening
PORTLAND, UNITED STATES
- OREGON HEALTH & SCIENCE UNIVERSITY — PORTLAND, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: SACHA, JONAH B. — OREGON HEALTH & SCIENCE UNIVERSITY
- Study coordinator: SACHA, JONAH B.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Acquired Immune Deficiency Syndrome Virus, Acquired Immunodeficiency Syndrome Virus